United Therapeutics Chairperson and CEO Martine Rothblatt disposes of USD 4.93 million in common shares

United Therapeutics Chairperson and CEO Martine Rothblatt disposed of shares worth approximately USD 4.93 million on July 23, 2026. She exercised options for 9,500 shares at USD 135.42, while a family trust sold 11,500 shares at prices between USD 522.87 and USD 531.83. Following these transactions, the trust's stake decreased to 324,443 shares, with Rothblatt holding an additional 40,513 shares directly.

United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 135.42 on July 23, 2026. * A family trust sold 11,500 shares the same day at weighted-average prices ranging from USD 522.87 to USD 531.83. * The trust’s common-stock stake fell to 324,443 shares following the sales. * The filing also showed 40,513 shares held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000105), on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 135.42 on July 23, 2026. * A family trust sold 11,500 shares the same day at weighted-average prices ranging from USD 522.87 to USD 531.83. * The trust’s common-stock stake fell to 324,443 shares following the sales. * The filing also showed 40,513 shares held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000105), on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here